3 results
Approved WMOWill not start
In a small pilot study to investigate possible occurence of blood chemistry deviations and / or a tamponade after the application of ACF-Matrix haemostat in the (L)IMA bed.
Approved WMOCompleted
To assess the local and systemic safety and tolerability of continued ABBV-951 treatment delivered as a CSCI for 24 hours daily.
Approved WMOCompleted
To assess the local and systemic safety and tolerability of ABBV-951 delivered as a CSCI for 24 hours daily for up to 52 weeks.